Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

WRN inhibitor RO7589831

An orally bioavailable and small molecule inhibitor of Werner syndrome ATP-dependent helicase (WRN; RecQ protein-like 2; Werner syndrome protein), with potential antineoplastic activity. Upon oral administration, WRN inhibitor RO7589831 covalently binds to and inhibits the activity of WRN. This may inhibit the growth of cancers with high microsatellite instability (MSI-H). WRN, a multifunctional enzyme with helicase, ATPase, and exonuclease activities, plays an important role in maintaining genome stability. Its helicase activity is essential for the survival of certain cancers with genomic microsatellite instability associated with defective DNA mismatch repair.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:WRN covalent inhibitor RO7589831
WRN inhibitor RG6457
Code name:RG 6457
RG-6457
RG6457
RO 7589831
RO-7589831
RO7589831
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search